SRRA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs...

Stats
Dagens volum	0.00
Gjennomsnittsvolum	651 457
Markedsverdi	0.00
EPS	$0 ( 2022-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.34
ATR14	$0.324 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2022-07-01	Vivo Opportunity, Llc	Sell	431 947	Common Stock
2022-07-01	Vivo Opportunity, Llc	Sell	75 749	Series A Warrants
2022-07-01	Orbimed Advisors Llc	Sell	226 704	Common Stock
2022-07-01	Orbimed Advisors Llc	Sell	170 437	Series A Warrants
2022-07-01	Ashiya Mona	Sell	226 704	Common Stock

INSIDER POWER
-97.17
Last 99 transactions
Buy: 4 604 902 \| Sell: 10 646 034

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: -0.71 (moderate negative)

Signal:(77.923) Neutral

Sierra Oncology Inc Korrelasjon

10 Mest positive korrelasjoner
TA	0.981
IIN	0.98
ECHO	0.98
MLVF	0.979
SIOX	0.972
ATCX	0.971
KRTX	0.969
MOR	0.968
EXFO	0.965
CRTO	0.963

10 Mest negative korrelasjoner
BIOL	-0.972
MRBK	-0.971
WTER	-0.971
CYXT	-0.971
PIII	-0.966
UTME	-0.965
BCAB	-0.963
SMFL	-0.961
UTMD	-0.958
RVSB	-0.957

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sierra Oncology Inc Korrelasjon - Valuta/Råvare

0.48
( neutral )

0.75
( moderate )

-0.14
( neutral )

0.32
( neutral )

0.60
( weak )

-0.68
( moderate negative )

Sierra Oncology Inc Økonomi

Annual	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2020
Omsetning:	$300 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-7.70

FY	2019
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-30.30

Financial Reports:

No articles found.

Sierra Oncology Inc

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.